Senolytic Therapy to Modulate Progression of Alzheimer's Disease
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib
(D) and quercetin (Q) [D+Q], penetrate the brain using cerebrospinal fluid (CSF) in older
adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown
to affect dying cells in humans with other chronic illnesses and in Alzheimer's mice models.
The study team want to know if this combination of medications will reach the brain in order
to evaluate if this intervention may be effective for treating AD symptoms in future studies.
This is also known as a "proof of concept" study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio